STOCK TITAN

Fulcrum Therapeutics (FULC) Financials

FULC NASDAQ
FY2025 annual
Revenue $0 -100.0% YoY
Net Income -$74.9M n/m YoY
EPS (Diluted) -$1.18 n/m YoY
Free Cash Flow -$60.4M n/m YoY
Market Cap $284.1M as of Nov 18, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 0.9x on $302.0M equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 18, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FULC SEC filings page.

Fulcrum Therapeutics, Inc. (FULC) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI FULC FY2025

Reported revenue can materially reshape losses, but the business still relies on external financing while research spending remains its core cost.

FY2024 paired reported revenue of $80M with operating cash flow of -$2.2M, showing that accounting improvement did not fully translate into cash generation. In FY2025, a net loss of $74.9M coincided with operating cash flow of -$60.1M, showing much tighter earnings-to-cash alignment.

The FY2024 revenue step-up did not make the cost base self-funding: research and development was $63.4M while operating margin remained -27.4%, indicating substantial development spending still sat ahead of reported profitability.

FY2025 assets reached $366.3M against $17.3M of liabilities, leaving the balance sheet lightly burdened by reported obligations. Financing cash flow of $168.7M alongside operating cash flow of -$60.1M indicates that financing inflows, rather than operations, funded the year's cash needs.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for Fulcrum Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Safe
7.96

Fulcrum Therapeutics, Inc. scores 7.96, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $284.1M against total liabilities of $17.3M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
2/7

Fulcrum Therapeutics, Inc. passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

Fulcrum Therapeutics, Inc. reported a net loss of $74.9M while operations used $60.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$13.6M
YoYn/m
QoQn/m

Fulcrum Therapeutics, Inc.'s EBITDA was -$13.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$10.9M
YoYn/m
QoQn/m
5Y CAGRn/m

Fulcrum Therapeutics, Inc. reported a net loss of $10.9M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.14
YoYn/m
QoQn/m
5Y CAGRn/m

Fulcrum Therapeutics, Inc. earned -$0.14 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$13.4M
YoYn/m
QoQn/m
5Y CAGRn/m

Fulcrum Therapeutics, Inc. recorded an outflow of $13.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$116.4M
YoY+147.3%
QoQ+140.2%
5Y CAGR+12.2%

Fulcrum Therapeutics, Inc. held $116.4M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
76M
YoY+41.1%
QoQ+0.1%
5Y CAGR+13.5%

Fulcrum Therapeutics, Inc. had 76M shares outstanding in Q3 2026. This represents an increase of 41.1% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-3.6%
YoY+6.3pp
QoQ+4.8pp
5Y change+5.4pp

Fulcrum Therapeutics, Inc.'s quarterly ROE was -3.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 6.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.8 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$3.0M
YoY-78.8%
QoQ-75.6%
5Y CAGR-29.2%

Fulcrum Therapeutics, Inc. invested $3.0M in research and development in Q3 2026. This represents a decrease of 78.8% from the same quarter a year earlier. Against the prior quarter it is down 75.6%.

Capital Expenditures
$0
YoY-100.0%
QoQ-100.0%

Fulcrum Therapeutics, Inc. reported no capital expenditure in Q3 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.

Share Buybacks

Not reported for Q3 2026.

FULC Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4Q3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4
RevenueN/AN/AN/AN/A$0n/m$0-100.0%N/A$0-100.0%
R&D Expenses$3.0M-78.8%$12.4M-4.2%$14.1M+5.1%$15.4M+31.6%$14.3M-2.3%$13.0M-24.8%$13.4M-32.2%$11.7M-38.3%
SG&A Expenses$8.4M+11.6%$7.5M+9.3%$8.1M+15.8%$7.3M-5.7%$7.6M-10.2%$6.8M-33.4%$7.0M-30.4%$7.7M-21.8%
Operating Income-$13.9Mn/m-$29.3Mn/m-$22.2Mn/m-$22.7Mn/m-$21.9Mn/m-$19.8M-137.7%-$20.4Mn/m-$19.4Mn/m
EBITDA-$13.6Mn/m-$29.1Mn/m-$21.8Mn/mN/A-$21.6Mn/m-$19.5M-136.9%-$20.1Mn/mN/A
Net Income-$10.9Mn/m-$26.2Mn/m-$18.9Mn/m-$20.3Mn/m-$19.6Mn/m-$17.3M-131.2%-$17.7Mn/m-$16.6Mn/m
EPS (Basic)-$0.14n/m-$0.34n/m-$0.25n/m-$0.31n/m-$0.31n/m-$0.28-131.5%-$0.28n/m-$0.27n/m
EPS (Diluted)-$0.14n/m-$0.34n/m-$0.25n/m-$0.31n/m-$0.31n/m-$0.28-132.2%-$0.28n/m-$0.27n/m
Diluted Shares (Avg)76M+21.9%76M+21.9%76M+22.0%N/A63M+0.3%63M-1.6%62M+0.8%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense, Income Tax.

FULC Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4Q3'2510-QQ2'2510-QQ1'25FilingQ4'24S-4
Total Assets$310.8M+44.7%$324.0M+41.6%$346.8M+42.9%$366.3M+40.5%$214.9M-23.0%$228.8M-22.2%$242.6M+4.3%$260.7M+1.2%
Current Assets$310.8M+51.0%$322.9M+47.2%$338.7M+45.6%$357.5M+43.0%$205.9M-23.0%$219.4M-21.7%$232.6M+6.7%$249.9M+3.2%
Cash & Equivalents$116.4M+147.3%$48.5M+13.8%$50.3M+19.2%$197.5M+239.3%$47.1M-35.2%$42.6M-50.9%$42.2M+5.6%$58.2M+127.7%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$8.8M-46.7%$13.3M-8.3%$13.5M-4.9%$17.3M-2.3%$16.5M-24.1%$14.5M-29.3%$14.2M-25.4%$17.7M-21.4%
Current Liabilities$8.6M-26.2%$10.3M+14.6%$9.9M+21.8%$13.0M+18.1%$11.6M-19.8%$9.0M-29.2%$8.1M-24.3%$11.0M-19.2%
Non-Current Liabilities$197K-95.9%$3.0M-46.0%$3.6M-40.6%$4.2M-36.2%$4.9M-32.6%$5.5M-29.5%$6.1M-27.0%$6.6M-24.8%
Total Equity$302.0M+52.3%$310.7M+44.9%$333.3M+45.9%$349.0M+43.6%$198.4M-22.9%$214.4M-21.7%$228.5M+7.0%$243.0M+3.3%
Retained Earnings-$650.3Mn/m-$639.3Mn/m-$613.2Mn/m-$594.3Mn/m-$573.9Mn/m-$554.3Mn/m-$537.1Mn/m-$519.4Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

FULC Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4Q3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4
Operating Cash Flow-$13.4Mn/m-$16.0Mn/m-$18.8Mn/m-$16.8Mn/m-$14.2Mn/m-$13.8M-123.5%-$15.3Mn/m-$16.8Mn/m
Depreciation & Amortization$300K0.0%$200K-33.3%$338K-4.2%$347K-6.0%$300K-25.0%$300K-25.0%$353K-26.3%$369K-27.4%
Stock-Based Compensation$2.2M-35.4%$3.3M+13.8%$3.9M+21.9%N/A$3.4M-12.0%$2.9M-33.8%$3.2M-19.1%N/A
Capital Expenditures$0-100.0%$108K+66.2%$8Kn/m$159K-31.2%$90K+373.7%$65Kn/m$0-100.0%$231K+200.0%
Free Cash Flow-$13.4Mn/m-$16.1Mn/m-$18.8Mn/m-$17.0Mn/m-$14.3Mn/m-$13.9M-123.6%-$15.3Mn/m-$17.0Mn/m
Investing Cash Flow$81.1M+335.9%$13.8M-1.1%-$128.2Mn/m-$1.0M-146.4%$18.6M+327.9%$13.9Mn/m-$777K-102.0%$2.3M-87.7%
Financing Cash Flow$198K+209.4%$356K+18.3%-$312Kn/m$168.3M+202673.5%$64K-89.9%$301K-20.2%$0-100.0%$83K-71.1%
Dividends Paid$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m

Not reported in any period shown, so not listed: Share Buybacks.

FULC Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

FULC quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'25S-4Q3'2510-QQ2'2510-QQ1'2510-QQ4'24S-4
Return on Equity-3.6%+6.3pp-8.4%-0.4pp-5.7%+2.1pp-5.8%+1.0pp-9.9%-1.4pp-8.1%-28.3pp-7.7%+4.9pp-6.8%+3.7pp
Return on Assets-3.5%+5.6pp-8.1%-0.5pp-5.5%+1.8pp-5.5%+0.8pp-9.1%-1.3pp-7.6%-26.4pp-7.3%+4.3pp-6.3%+3.3pp
Current Ratio36.19+18.5x31.35+6.9x34.33+5.6x27.40+4.8x17.70-0.7x24.42+2.3x28.71+8.3x22.63+4.9x
Liabilities-to-Equity0.03-0.1x0.040.0x0.040.0x0.050.0x0.080.0x0.070.0x0.060.0x0.070.0x
Asset TurnoverN/AN/AN/AN/A0.000.0x0.00-0.3xN/A0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
Fulcrum Therapeutics, Inc. FULC FY2025 $0 -$74.9M N/A $284.1M —
Ocugen, Inc. OCGN FY2025 $4.4M -$67.8M N/A $250.8M 43/100
Prelude Therapeutics Incorporated PRLD FY2025 $12.1M -$99.5M N/A $264.1M 73/100
Century Therapeutics, Inc. IPSC FY2025 $109.2M -$9.6M -8.8% $250.6M 60/100
Allogene Therapeutics, Inc. ALLO FY2025 $0 -$190.9M N/A $241.1M —
Cabaletta Bio, Inc. CABA FY2025 N/A -$167.9M N/A $227.6M —

Frequently Asked Questions

Fulcrum Therapeutics, Inc. (FULC) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

Fulcrum Therapeutics, Inc. (FULC) revenue declined by 100.0% year-over-year, from $80.0M to $0 in fiscal year 2025.

No, Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $74.9M in fiscal year 2025.

Fulcrum Therapeutics, Inc. (FULC) reported diluted earnings per share of -$1.18 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Fulcrum Therapeutics, Inc. (FULC) had EBITDA of -$83.4M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

Fulcrum Therapeutics, Inc. (FULC) has a return on equity of -21.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

Fulcrum Therapeutics, Inc. (FULC) recorded an outflow of $60.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

Fulcrum Therapeutics, Inc. (FULC) recorded an outflow of $60.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

Fulcrum Therapeutics, Inc. (FULC) had $366.3M in total assets as of fiscal year 2025, including both current and long-term assets.

Fulcrum Therapeutics, Inc. (FULC) invested $314K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

Fulcrum Therapeutics, Inc. (FULC) invested $56.1M in research and development during fiscal year 2025.

Fulcrum Therapeutics, Inc. (FULC) had 67M shares outstanding as of fiscal year 2025.

Fulcrum Therapeutics, Inc. (FULC) had a current ratio of 27.40 as of fiscal year 2025, which is generally considered healthy.

Fulcrum Therapeutics, Inc. (FULC) had a liabilities-to-equity ratio of 0.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

Fulcrum Therapeutics, Inc. (FULC) had a return on assets of -20.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Fulcrum Therapeutics, Inc. (FULC) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $284.1M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

Fulcrum Therapeutics, Inc. (FULC) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $284.1M as of Nov 18, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, Fulcrum Therapeutics, Inc. (FULC) held $197.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $60.1M over that year. Dividing the one by the other, the reported balance equals about 39 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Fulcrum Therapeutics, Inc. (FULC) has an Altman Z-Score of 7.96, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

Fulcrum Therapeutics, Inc. (FULC) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Fulcrum Therapeutics, Inc. (FULC) reported a net loss of $74.9M while operations used $60.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top